Opendata, web and dolomites

MYCure SIGNED

Innovative cancer therapy through Myc inhibition: taking OMO-103 to market

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MYCure project word cloud

Explore the words cloud of the MYCure project. It provides you a very rough idea of what is the project "MYCure" about.

models    combines    poised    redundant    toxic    scientific    peptomyc    therapies    rounds    millions    thanks    clinical    investments    gain    patented    deaths    103    treatments    attack    nuclei    revolutionizing    venture    70    world    licensing    compensated    14    resistance    company    addressable    efficient    innovative    inhibition    sound    bn    considerable    20    toxicity    annually    2023    myc    sme    surface    kill    excellence    completing    safer    accounting    ground    penetrate    breaking    first    small    biotech    share    record    instrument    2029    lung    treatment    global    cells    proteins    contrast    inhibitor    ineffective    class    equity    women    closed    mycure    companies    despite    plan    omo    clear    acumen    men    2018    cancer    full    leadership    trials    tumours    pressing    inhibiting    cell    pharmaceutical    treat    too    foundation    total    projected    receptors    builds    15    evolve    business    capitals    commercialization    survival    market    financing   

Project "MYCure" data sheet

The following table provides information about the project.

Coordinator
PEPTOMYC SL 

Organization address
address: CENTER CELLEX, CALLE NATZARET 115-117
city: BARCELONA
postcode: 8035
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙170˙790 €
 EC max contribution 2˙219˙553 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PEPTOMYC SL ES (BARCELONA) coordinator 2˙219˙553.00

Map

 Project objective

Cancer is a global challenge with 9 millions (M) deaths annually and new cases projected to rise by 70% in the 20 years, and there is a clear and pressing need for more effective therapies. In the EU, lung cancer is the most common cancer in men and the third most common in women, with 2 M new cases in 2018 accounting for ~20% of all cancer deaths. Despite considerable recent advances in lung cancer treatment, current treatments are still too often ineffective or highly toxic. Peptomyc is a unique biotech SME that is revolutionizing cancer treatment with its ground-breaking innovative cancer therapies inhibiting Myc. Our patented product OMO-103 is able to penetrate the nuclei, attack Myc and kill cancer cells. In contrast, most current therapies attack redundant cell surface receptors or proteins that can be compensated by tumours, which then evolve resistance. Our company combines scientific excellence with sound business acumen: our scientific leadership in Myc inhibition builds on 20 years of world-class scientific record, and in just 3 years after the foundation, we closed 2 rounds of equity investments with Venture Capitals. Peptomyc aims at licensing its technology to pharmaceutical companies. Financing through this SME Instrument project will enable us to take to the market our first product, OMO-103 by completing clinical trials and reach a licensing agreement with a pharmaceutical company for full scale production and commercialization. Our results so far show that OMO-103 is: Safer (no toxicity), More efficient (no resistance observed), and More effective (increased survival in lung cancer models). With MYCure, we will take to market our first-in-class Myc inhibitor OMO-103 to treat non-small cell lung cancer, for which the global market is expected to reach 14 bn € by 2023, a total addressable market of which OMO-103 is poised to gain considerable share of up to 15% by 2029 thanks to a sound business plan developed under the SME Instrument.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYCURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYCURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

Path Feel (2019)

Insoles for Neuropathy and Balance Issues

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More